CN
Home
Home
About Us
About Us
Ark Overview
Our Team
Our History
Our Culture
Our Advisors
Research
Research
Pipeline
Pipeline
Media
Media
Ark News
Career
Career
Contact Us
Contact Us
Investor relations
Investor relations
Corporate Governance
Board Members
Announcements and Circulars
Stock Information
IR
Home
About Us
Ark Overview
Our Team
Our History
Our Culture
Our Advisors
Research
Pipeline
Media
Ark News
Career
Contact Us
Investor relations
Corporate Governance
Board Members
Announcements and Circulars
Stock Information
IR
Ark News
2023
2022
2021
2020
2019
2018
2023-03-16
Ark Biopharmaceutical and Calibr, a Division of Scripps Research, Announce Co-development Collaboration on AK0705, a Potential First-in-Class Drug for Treating a Broad Spectrum of Respiratory Diseases, Including COPD
Shanghai Ark Biopharmaceutical Co., Ltd. today announced that it has renewed its co-development collaboration with Calibr, a division of Scripps Research. The collaboration centers on AK0705, a potential first-in-class drug targeting an enzyme that plays an important role in respiratory inflammation. AK0705 is being developed to treat a broad spectrum of respiratory diseases, including chronic obstructive pulmonary disease (COPD).
Prev
1
Next
TOP
Home
Tel
Top
TOP
Telephone：
Address：
E-mail：
CN
